Psoriasis Pipeline Analysis, 2025 Delveinsight Mylan, Biocad, Bristol-Myers Squibb, Celltrion, Coherus Biosciences, Janssen Pharmaceuticals, Can-Fite Biopharma, Arcutis Biotherapeutics, Amgen, Iltoo

(MENAFN- GetNews)


"Psoriasis Pipeline Analysis"DelveInsight's,“Psoriasis- Pipeline Insight, 2025” report provides comprehensive insights about 65+ companies and 75+ pipeline drugs in Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

According to DelveInsight, over 65 leading companies are actively developing more than 75 therapies targeting psoriasis, reflecting a robust and dynamic pipeline.

Psoriasis Overview:

Psoriasis is a chronic, immune-mediated skin disorder characterized by the rapid buildup of skin cells, leading to thick, red, scaly patches. It can affect any part of the body, commonly the elbows, knees, scalp, and lower back, and is often associated with itching, discomfort, and psychological stress. The disease can range from mild to severe and may be linked with comorbidities such as psoriatic arthritis, cardiovascular disease, and metabolic syndrome. While the exact cause is not fully understood, psoriasis involves an overactive immune response, particularly involving T-cells and inflammatory cytokines. Current treatments focus on topical therapies, phototherapy, systemic medications, and biologics, aimed at controlling symptoms and preventing flare-ups.

Download our report @

"Psoriasis Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Psoriasis Therapeutics Market.

Key Takeaways from the Psoriasis Pipeline Report

• DelveInsight's Psoriasis pipeline report depicts a robust space with 65+ active players working to develop 75+ pipeline therapies for Psoriasis treatment.

• Key Psoriasis companies such as Can-Fite Biopharma, Huabo Biopharm Co., Ltd., MoonLake Immunotherapeutics, E-nitiate Biopharmaceuticals, Chia Tai Tianqing Pharmaceutical Group, BioRay Pharmaceutical Co., Ltd., SFA Therapeutics, Rubedo Life Sciences, Inc, and others are evaluating new drugs for Psoriasis to improve the treatment landscape.

• Promising Psoriasis pipeline therapies in various stages of development include Piclidenoson, Sonelokimab, QY101, SFA 002, RLS-1496, and others.

Psoriasis Pipeline Analysis

The Psoriasis pipeline insights report 2025, provides insights into:

• Provides comprehensive insights into key companies developing therapies in the Psoriasis Market.

• Categorizes Psoriasis therapeutic companies by development stage: early, mid, and late-stage.

• Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.

• Reviews emerging Psoriasis drugs under development based on:

  • Stage of development

  • Psoriasis Route of administration

  • Target receptor

  • Monotherapy vs. combination therapy

  • Psoriasis Mechanism of action

  • Molecular type

• Offers detailed analysis of:

  • Company-to-company and company-academia collaborations

  • Psoriasis Licensing agreements

  • Funding and investment activities supporting future Psoriasis market advancement.

Request for a sample report @

Psoriasis Emerging Drugs

• RLS-1496: Rubedo Life Sciences, Inc

• SFA 002: SFA Therapeutics

• QY101: E-nitiate Biopharmaceuticals

• Sonelokimab: MoonLake Immunotherapeutics

• Piclidenoson: Can-Fite Biopharma

Psoriasis Companies

Approximately 65+ leading companies are actively developing therapies for psoriasis. Among them, those with drug candidates in the most advanced stage (Phase III) include Can-Fite Biopharma.

DelveInsight's report covers around 80+ products under different phases of Psoriasis clinical trials like

• Psoriasis Late stage Therapies (Phase III)

• Psoriasis Mid-stage Therapies (Phase II)

• Psoriasis Early-stage Therapies (Phase I)

• Psoriasis Pre-clinical and Psoriasis Discovery stage Therapies

• Psoriasis Discontinued & Inactive Therapies

Psoriasis pipeline report provides the Psoriasis therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous

• Subcutaneous

• Oral

• Intramuscular

Psoriasis Products have been categorized under various Molecule types such as

• Monoclonal antibody

• Small molecule

• Peptide

Download Sample Pages to Get an in-depth Assessment of the Emerging Psoriasis Therapies and Key Psoriasis Companies: Psoriasis Clinical Trials and recent advancements

Psoriasis Pipeline Therapeutic Assessment

. Psoriasis Assessment by Product Type

. Psoriasis By Stage

. Psoriasis Assessment by Route of Administration

. Psoriasis Assessment by Molecule Type

Download Psoriasis Sample report to know in detail about the Psoriasis treatment market @ Psoriasis Therapeutic Assessment

Table of Content

1. Report Introduction

2. Executive Summary

3. Psoriasis Current Treatment Patterns

4. Psoriasis - DelveInsight's Analytical Perspective

5. Therapeutic Assessment

6. Psoriasis Late-Stage Products (Phase-III)

7. Psoriasis Mid-Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Psoriasis Discontinued Products

13. Psoriasis Product Profiles

14. Psoriasis Key Companies

15. Psoriasis Key Products

16. Dormant and Discontinued Products

17. Psoriasis Unmet Needs

18. Psoriasis Future Perspectives

19. Psoriasis Analyst Review

20. Appendix

21. Report Methodology

Request the Sample PDF to Get Detailed Insights About the Psoriasis Pipeline Reports Offerings:

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

MENAFN04092025003238003268ID1110020069